Cytogenetic and Molecular Failure at 12 Months will be the Optimal Time Point for BCR-ABL1 Tyrosine Kinase Domain Mutation Analysis in Patients with Chronic Myeloid Leukemia: The Analysis Based on 2013 European LeukemiaNet Recommendation
BCR-ABL1 kinase domain mutations are closely related to tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML). Although mutation analysis has been recommended in CML patients with treatment failure, there is no standard guideline according to landmark responses at specific timepoints of European LeukemiaNet (ELN) recommendation.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Hee-Je Kim, Hea-Lyun Yoo, Won-Sik Lee, Hyeong-Joon Kim, Jee Hyun Kong, Yunsuk Choi, Young Rok Do, Jae-Yong Kwak, Sukjoong Oh, Sung Hyun Kim, Jeong-A. Kim, Dae Young Zang, Yeung-Chul Mun, Young-Woong Won, Sung-Eun Lee, Dong-Wook Kim Source Type: research